BioCryst Pharmaceuticals, Inc. (BCRX) Stock Split, History Data
Working capital analysis
In terms of working capital, BioCryst Pharmaceuticals, Inc. maintains a healthy position.
The total current assets of the company are valued at $495966000.
This represents a growth rate of -3.976% compared to the previous year.
Breaking down the current assets, the cash and investments are worth $112447000, exhibiting a growth rate of -63.104% year-on-year.
The receivables, another significant portion of the current assets, are valued at $56950000.
The year-on-year growth rate for receivables is 12.552%.
The inventory, which forms a critical part of the assets, is valued at $28683000.
This represents a healthy year-on-year growth of 4.177%
On the liabilities side, the company's current liabilities total $149988000.
This reflects a growth rate of 42.150% over the previous year, indicating the company's financial obligations are well under control.
2023
2022
2021
2020
2019
2018
Cash and investments
112.45
304.77
504.39
272.13
114.17
26.73
Receavebles
56.95
50.60
29.41
8.65
22.15
4.29
Inventory
28.68
27.53
15.79
7.04
1.55
1.65
Other
19.54
12.59
9.99
5.53
4.42
2.39
Total Current Assets
495.97
516.50
566.14
323.80
164.34
114.35
Acc Payable
20.89
14.36
27.81
18.71
13.99
7.77
Short Term Debt
26.21
2.37
1.82
31.18
39.96
33.75
Other Current Liab
102.88
87.56
72.67
55.61
36.27
27.74
Current Liabilities
149.99
105.51
103.72
105.65
92.33
69.48
Capital Structure
When examining the capital structure of BioCryst Pharmaceuticals, Inc., it is clear that the company manages a robust portfolio.
The value of their total assets clocks in at $516960000.
When juxtaposed with the previous year, this marks a growth rate of -6.007%, showcasing the company's ability to steadily grow its asset base.
Turning to liabilities, the company has total liabilities amounting to $972488000.
Compared to the prior year, this reflects a growth rate of 15.142%.
The long-term debt forms a sizable part of these liabilities, coming in at $811265000.
Over the last year, the long-term debt has grown by 9.766%.
On the asset side, the cash and equivalent reserves are worth $112447000.
The year-on-year growth of these reserves is -63.104%.
The company's common stock, another important asset, holds a value of $2057999, growing at a rate of 9.526% from the previous year.
Finally, the company's retained earnings stand at $-1681159000, marking a growth rate of 15.574% year-over-year.
These earnings represent the profits that BioCryst Pharmaceuticals, Inc. has chosen to reinvest in the business rather than distribute as dividends.
Total Assets
$516.96
Total liabilities
$972,488,000.00
Long term debt
$811.26
Cash and eqv
$112,447,000.00
Goodwill
$0.00
Retained earnings
-$1,681,159,000.00
Common stock
$0.00
Enterprise Value
-$2.25
Net earnings per share (EPS)
BioCryst Pharmaceuticals, Inc. has an EPS of $-1.18, which signifies the profit allocated per share of common stock. With a growth rate of 11.278% this year, it indicates the company's increasing profitability and potential for share value growth. This trend signals robust financial performance and future potential.
